GLP-1 Agonists Show Promise in Cancer Risk Reduction, New Studies Suggest

Recent research presented at the American Society of Clinical Oncology (ASCO) conference and published in *JAMA Oncology* suggests that GLP-1 agonists—medications initially developed for diabetes and weight loss—may reduce the risk of certain cancers, including lung, breast, and colorectal cancer, according to findings from multiple studies. These drugs, including Wegovy and Mounjaro, are now under scrutiny for their potential role in cancer prevention, beyond their established use in managing obesity and blood sugar levels.

What Do Recent Studies Reveal?

A study presented at ASCO analyzed data from over 111,000 women and found that those treated with GLP-1 agonists had a 30% lower risk of breast cancer compared to those on other diabetes medications, according to Elizabeth McDonald of the University of Pennsylvania. Another analysis published in *JAMA Oncology* linked GLP-1 agonists to a significantly lower risk of colorectal cancer, particularly among patients with obesity, a known risk factor for the disease.

Observational data from the ASCO conference also indicated that 90% of patients with lung and breast cancer treated with GLP-1 agonists avoided metastasis, while 87% of colorectal cancer patients and 81% of liver cancer patients remained metastasis-free. However, researchers emphasize that these findings are based on observational data and require confirmation through randomized controlled trials.

How Do GLP-1 Agonists Work to Reduce Cancer Risk?

Scientists hypothesize that GLP-1 agonists may lower cancer risk through two primary mechanisms. First, they promote weight loss, which addresses obesity—a major contributor to several cancers. Second, they exhibit anti-inflammatory and immune-modulating properties that could directly inhibit cancer development, according to the *JAMA Oncology* study.

“The dual effects of weight reduction and biological activity make GLP-1 agonists a compelling area for further investigation,” said Dr. Emily Chen, a cancer researcher at the National Cancer Institute, who was not involved in the studies. “However, more research is needed to understand the exact pathways involved.”

What Are the Implications for Cancer Treatment?

While GLP-1 agonists are not poised to replace traditional cancer therapies like chemotherapy or immunotherapy, they could play a supportive role in prevention and post-treatment care. Researchers suggest that these drugs might be particularly valuable for high-risk populations, such as individuals with obesity or a family history of certain cancers.

“The findings highlight the importance of addressing modifiable risk factors like obesity in cancer prevention,” said Dr. Sarah Lin, a public health expert at the University of California, San Francisco. “However, patients should not interpret these results as a substitute for established screening protocols or medical advice.”

What’s Next for Research?

Experts caution that the current evidence, while promising, is not yet sufficient to recommend GLP-1 agonists as a standard cancer preventive measure. Larger, long-term studies are needed to confirm the observed benefits and assess potential side effects. The American Cancer Society and the Endocrine Society have both called for further investigation into the relationship between these medications and cancer risk.

As the scientific community continues to explore this emerging area, patients and healthcare providers are advised to stay informed about developments in this field. For now, the focus remains on rigorous clinical trials to determine whether GLP-1 agonists can become a valuable tool in the broader fight against cancer.